¼¼°èÀÇ ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®
Deep Brain Stimulation Market Forecast to 2030 - Global Analysis by Product, Application, and End User
»óǰÄÚµå : 1347150
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 168 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,285,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,110,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,935,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

³ú½ÉºÎ ÀÚ±Ø(Deep Brain Stimulation) ½ÃÀå ±Ô¸ð´Â 2022³â 6¾ï 352¸¸ ´Þ·¯¿¡¼­ 2030³â 11¾ï 5,537¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022-2030³â »çÀÌ CAGRÀº 8.5%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

³ú½ÉºÎ ÀÚ±Ø(DBS)Àº ³úÀÇ ÀϺΠ¿µ¿ª¿¡ Àü±âÀû ÀÚ±ØÀ» ÁÖ°í ¿îµ¿À» Á¦¾îÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀåÄ¡¸¦ ÀǹÌÇÕ´Ï´Ù. ÆÄŲ½¼º´, ¸¸¼º ÅëÁõ, ÁßÃß¼º ÅëÁõ ÁõÈıº, °£Áú, °­¹Ú¼º Àå¾Ö µî Ä¡·á¿¡ ³Î¸® ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ú½ÉºÎ ÀÚ±ØÀº ´Ù¾çÇÑ ½Å°æ ÁúȯÀ¸·Î ÀÎÇÑ °æÁ÷, Áö¿¬, º¸Çà Àå¾Ö¿Í °°Àº Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ¼ºÀåÀº ½Å°æÁúȯÀÇ À¯º´·ü »ó½Â°ú Àúħ½À ¼ö¼ú ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

·Îº¿ À̽Ä, ¸ÖƼ Ÿ°Ù ÀÚ±Ø, ¹Ì¼¼ Àü±Ø ¼³°è °³¼±, ÃæÀü½Ä ÆÞ½º ¹ß»ý±â, °³º°È­ µÈ Ÿ°Ù ÇÁ·Î±×·¡¹Ö µîÀº ³ú½ÉºÎ ÀÚ±ØÀÇ ±â¼úÀû Áøº¸ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸·Î ³ú½ÉºÎ ÀÚ±Ø ÀåÄ¡´Â ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í ÆÄŲ½¼º´ ȯÀÚÀÇ È¿´É°ú Áõ»ó ¿ÏÈ­°¡ °³¼±µÇ¾ú½À´Ï´Ù. AbbotÀÇ ÀÎÇÇ´ÏÆ¼ ³ú ½ÉºÎ ÀÚ±Ø ½Ã½ºÅÛÀº ȯÀÚÀÇ Áõ»ó °ü¸®¸¦ µ½´Â ±â¼úÀûÀ¸·Î Áøº¸µÈ »õ·Î¿î ³ú½ÉºÎ ÀÚ±ØÀÔ´Ï´Ù. ÀÌ´Â È¿À²ÀûÀÌ°í °³ÀÎÈ­µÈ Ä¡·á °ü¸®¸¦ Á¦°øÇÏ°í ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÎ ÃÖÃÊÀÇ ¹«¼± iOS ¼ÒÇÁÆ®¿þ¾î ³ú½ÉºÎ ÀÚ±Ø ¸ð¹ÙÀÏ Ç÷§ÆûÀÔ´Ï´Ù.

¶ÇÇÑ ÁøÀü, ½É°¢ÇÑ °­¹Ú Àå¾Ö, ±Ù±äÀå ±ÙÀ° µî ÀÓ»ó ÀÀ¿ë ºÐ¾ß¿¡¼­ ³ú½ÉºÎ ÀÚ±Ø ÀåÄ¡ÀÇ FDA ½ÂÀÎÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 3¿ù, ´º·ÎÆäÀ̽º´Â ¹Ì±¹ FDA·ÎºÎÅÍ RNA ½Ã½ºÅÛÀÇ MRI ¶óº§ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

2020³â 2¿ù¿¡ ¹ßÇ¥µÈ MGM HealthcareÀÇ º¸µµ ÀÚ·á¿¡ µû¸£¸é, Ÿ¹Ð ³ªµÎÀÇ MGM Healthcare´Â °­¹Ú¼º Àå¾Ö(OCD)¿¡ ´ëÇÑ ÃÖÃÊÀÇ ³ú½ÉºÎ ÀÚ±ØÀ» ½ÃÇàÇß½À´Ï´Ù. µû¶ó¼­ ³ú½ÉºÎ ÀÚ±ØÀÇ ±â¼úÀû Áøº¸´Â ¿¹Ãø±â°£ µ¿¾È ¼¼°èÀÇ ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå¿¡ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ¾ÆÆ²¶ó½º, À̹Ì¡ ±â¼ú, Ä¿³ØÆ®¹Í½ºÀÇ Áøº¸´Â ³ú½ÉºÎ ÀÚ±ØÀÇ Ç¥Àû Àü·«À» °³¼±ÇÕ´Ï´Ù. ¸®µå ¼³°è °³¼±À¸·Î ÁöÇ⼺ ÀÚ±ØÀ» À§ÇØ ºÎ¹®È­µÈ Á¢Á¡À» »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç, À̽ÄÇü ÆÞ½º ¹ß»ý±â(IPG) ¼³°è °³¼±À¸·Î ÀÛ°í ±ä ¼ö¸íÀÇ Àڱ⠰ø¸í ¿µ»ó(MRI) ȣȯ ¹èÅ͸®°¡ ½ÇÇöµË´Ï´Ù. ¼ÒÇÁÆ®¿þ¾îÀÇ Áøº¸´Â Àڱذú °ü·ÃµÈ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ°í ¹èÅ͸® ¼ö¸íÀ» ±Ø´ëÈ­Çϸ鼭 È¿°ú¸¦ Çâ»ó½ÃŰ´Â ´Ù¾çÇÑ ÇÁ·Î±×·¡¹Ö Àü·«À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ³ú ÀνÄÀº ÀÓ»óÀÇ¿Í ¿¬±¸¿øÀÌ ³ú½ÉºÎ ÀÚ±ØÀÇ »ý¸®Àû Ãø¸éÀ» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç ´Ù¸¥ ÇÁ·Î±×·¡¹Ö Àü·«À¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Æó¼â ·çÇÁ ³ú½ÉºÎ ÀÚ±ØÀº °³º° Áõ»ó¿¡ µû¶ó ÀÚ±Ø ¸Å°³ º¯¼ö¸¦ Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ¿ø°Ý Á¶ÀÛ ¹× °¡»ó ÇÁ·Î±×·¡¹ÖÀÌ ´õ Çö½ÇÀûÀÌ°í »ç¿ëÇϱ⠽¬¿öÁú ¼ö ÀÖ½À´Ï´Ù. ³ú½ÉºÎ ÀÚ±Ø ±â¼úÀº ´Ù¾çÇÑ Áúȯ ¹× Áõ»óÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÇöÀçÀÇ ¼³°è¸¦ °³¼±Çϱâ À§ÇÑ ¿¬±¸°¡ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. 2023³â 3¿ù, ¹Ì½Ã°£°ø°ú´ëÇÐÀÇ ¿¬±¸ÀÚµéÀº ´º·Î¸ðÇÈ ÄÄÇ»ÆÃÀ» ÀÌ¿ëÇÏ¿© ÆÄŲ½¼º´ Ä¡·á¿¡ »ç¿ëµÇ´Â ³ú½ÉºÎ ÀÚ±Ø ½Ã½ºÅÛÀÇ È¿´É°ú ¿¡³ÊÁö È¿À²À» °³¼±Çß½À´Ï´Ù. ±×·¯¹Ç·Î ³ú½ÉºÎÀÚ±Ø ºÐ¾ß¿¡¼­ R&D Ȱµ¿ Áõ°¡´Â ÇâÈÄ ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ ±â¹Ý ÅëÂû·Â

ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î ³ú½ÉºÎ ÀÚ±Ø ½ÃÀåÀº º´¿ø, ½Å°æ°ú Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿ø ºÎ¹®Àº ÆÄŲ½¼º´ ¹× ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº ´Ù¾çÇÑ ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡¿Í º´¿ø ȯ°æ¿¡¼­ ¼÷·ÃµÈ Àü¹®°¡ÀÇ ¹Ø¿¡¼­ È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ±âŸ Áúȯ¿¡ ÀÇÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º´¿ø¿¡¼­ ÁøÇàµÇ´Â ³ú½ÉºÎ ÀÚ±Ø ¼ö¼úÀÇ ¼ö´Â Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2021³â¿¡ ¹ßÇ¥µÈ 'Single-Stage Deep Brain Stimulator Placement for Movement Disorders'¶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é ¼¼°è ¾à 16¸¸ ¸íÀÇ È¯ÀÚ°¡ ´Ù¾çÇÑ ½Å°æÇÐÀû ¹× ºñ½Å°æÇÐÀû Áúȯ¿¡ ³ú½ÉºÎ ÀÚ±ØÀ» ¹Þ°í ÀÖÀ¸¸ç, ¸Å³â-12,000¸íÀÇ È¯ÀÚ°¡ »õ·Ó°Ô ³ú½ÉºÎ ÀÚ±ØÀ» ¹Þ¾Ò½À´Ï´Ù.

¶ÇÇÑ, ³ú½ÉºÎ ÀÚ±Ø ¼ö¼ú¿¡´Â ¸Å¿ì Á¤È®Çϰí È¿À²ÀûÀÎ ÀÇ·á Á¶Ä¡°¡ ÇÊ¿äÇÕ´Ï´Ù. º´¿ø¿¡¼­ ´õ ³ªÀº Ä¡·á ½Ã¼³°ú °í±Þ ³ú½ÉºÎ ÀÚ±Ø ÀåÄ¡¸¦ »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÌ È¯ÀÚ°¡ º´¿ø¿¡¼­ ½Å°æ ÇÐÀû Ä¡·á¸¦ ¿ä±¸ÇÏ´Â Å« ÀÌÀ¯°¡µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ º´¿ø¿¡¼­ ¼÷·ÃµÈ °æÇèÀÌ Ç³ºÎÇÑ ½Å°æ°ú ÀÇ»ç, °£È£»ç, ±â¼úÀÚ µî ÃÖ°í ǰÁúÀÇ Àü¹® Á÷¿øÀÌ Æí¾ÈÇÑ È¯°æ¿¡¼­ ȯÀÚ¿¡°Ô ÃÖ°íÀÇ ¼ö¼ú Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ±×·¯¹Ç·Î ¾Õ¼­ ¾ð±ÞÇÑ ¸ðµç ¿äÀεéÀº ¾ÕÀ¸·Î ¼ö³â°£ ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO), ±¹¸³À§»ý¿¬±¸¼Ò(NIH), Neurological Health Charities Canada(NHCC) µîÀº ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå º¸°í¼­ ÀÛ¼º ½Ã¿¡ ÂüÁ¶ÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸¿øÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå »óȲ

Á¦5Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå-ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦6Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå : ½ÃÀå ºÐ¼®

Á¦7Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå-Á¦Ç°º° ¼öÀÍ ¹× ¿¹Ãø(-2030³â)

Á¦8Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå : ¿ëµµº° ¼öÀÍ ¹× ¿¹Ãø(-2030³â)

Á¦9Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº° ¼öÀÍ ¹× ¿¹Ãø(-2030³â)

Á¦10Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦11Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

Á¦12Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå »ê¾÷ Á¤¼¼

Á¦13Àå ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå : ÁÖ¿ä ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The deep brain stimulation market size is expected to grow from US$ 603.52 million in 2022 to US$ 1,155.37 million by 2030; it is estimated to record a CAGR of 8.5% from 2022 to 2030.

Deep brain stimulation (DBS) refers to a device used for the purpose of providing electrical incitement to some areas of the brain to control the movement. They are extensively utilized to treat diseases such as Parkinson's disease, chronic pain, central pain syndrome, epilepsy, and obsessive-compulsive disorder among others. DBS helps in reducing the symptoms of stiffness, slowness, and walking problems caused by various neurological diseases. The deep brain stimulation market growth is attributed to the rising prevalence of neurological disorders and increasing demand for minimally invasive surgery.

Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in DBS. Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects.

In addition, there is an increase in FDA approvals for DBS devices in clinical applications such as tremors, severe obsessive-compulsive disorder, and dystonia. For instance, in March 2020, NeuroPace, Inc. received approval from the US FDA for MRI labeling its RNA system.

According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first DBS for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the global deep brain stimulation market during the forecast period.

Further, advances in atlases, imaging techniques, and connectomics improve DBS targeting strategies. Improvements in lead design can make it possible to use segmented contacts for directional stimulation, and improvements in implantable pulse generator (IPG) design can result in small, longer-lasting magnetic resonance imaging (MRI) compatible batteries. Software advances can enable various programming strategies to improve efficacy while minimizing stimulation-related side effects and maximizing battery life. Brain recognition will help clinicians and researchers understand the physiological aspects of DBS and potentially act as another programming strategy. Closed-loop DBS can help tailor stimulation parameters to individual symptoms. In addition, remote and virtual programming could become more viable and accessible. DBS technology is widely used to treat various diseases and symptoms, and research is ongoing to improve current designs. In March 2023, researchers at Michigan Technological University used neuromorphic computing to improve the efficacy and energy efficiency of deep brain stimulation systems used to treat Parkinson's disease. Therefore, rising research and development activities in the field of deep brain stimulation are expected to bolster the deep brain stimulation market growth in the future.

End User -Based Insights

Based on end user, the deep brain stimulation market is categorized into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment accounted for the largest market share, and is anticipated to register the highest CAGR during the forecast period. The hospitals segment is expected to grow significantly owing to the rising prevalence of various neurological conditions such as Parkinson's and Alzheimer's disease and other disorders that can be treated effectively under skilled professionals in hospital settings. There is an increase in the number of DBS surgeries performed in hospitals. As per a study titled "Single-Stage Deep Brain Stimulator Placement for Movement Disorders," published in 2021, approximately 160,000 patients worldwide have undergone DBS for various neurological and non-neurological conditions, and ~12,000 new patients receive DBS annually.

Moreover, DBS surgeries require extreme precision and efficient medical attention; the availability of better treatment facilities at the hospitals and advanced DBS devices is a significant reason that is pushing patients to seek neurological treatments in hospital settings. In addition, hospitals also employ the highest quality of professional staff, including skilled and experienced neurologists, nurses, and technicians, that work together to provide patients with the best surgical care in a pleasant environment. Therefore, all the above-mentioned factors are expected to promote the deep brain stimulation market growth in the coming years.

The World Health Organization (WHO), National Institutes of Health (NIH), and Neurological Health Charities Canada (NHCC) are among the primary and secondary sources referred to while preparing the deep brain stimulation market report.

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Deep Brain Simulation Market Landscape

5. Deep Brain Simulation Market - Key Industry Dynamics

6. Deep Brain Simulation Market - Global Market Analysis

7. Global Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Product

8. Global Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Application

9. Global Deep Brain Simulation Market - Revenue and Forecast to 2030 - by End User

10. Deep Brain Simulation Market - Geographical Analysis

11. Pre & Post Covid-19 Impact

12. Deep Brain Simulation Market Industry Landscape

13. Deep Brain Simulation Market, Key Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â